These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 30388424)

  • 21. Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
    Uyanik B; Goloudina AR; Akbarali A; Grigorash BB; Petukhov AV; Singhal S; Eruslanov E; Chaloyard J; Lagorgette L; Hadi T; Baidyuk EV; Sakai H; Tessarollo L; Ryffel B; Mazur SJ; Lirussi F; Garrido C; Appella E; Demidov ON
    Nat Commun; 2021 Jun; 12(1):3622. PubMed ID: 34131120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct landscape and clinical implications of therapy-related clonal hematopoiesis.
    Takahashi K; Nakada D; Goodell M
    J Clin Invest; 2024 Oct; 134(19):. PubMed ID: 39352380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
    Arends CM; Kopp K; Hablesreiter R; Estrada N; Christen F; Moll UM; Zeillinger R; Schmitt WD; Sehouli J; Kulbe H; Fleischmann M; Ray-Coquard I; Zeimet A; Raspagliesi F; Zamagni C; Vergote I; Lorusso D; Concin N; Bullinger L; Braicu EI; Damm F
    Leukemia; 2024 Jun; 38(6):1378-1389. PubMed ID: 38637689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse.
    Al Hinai ASA; Grob T; Rijken M; Kavelaars FG; Zeilemaker A; Erpelinck-Verschueren CAJ; Sanders MA; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    Leukemia; 2021 Sep; 35(9):2693-2697. PubMed ID: 33589749
    [No Abstract]   [Full Text] [Related]  

  • 25. Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.
    Burocziova M; Danek P; Oravetzova A; Chalupova Z; Alberich-Jorda M; Macurek L
    Leukemia; 2023 Nov; 37(11):2209-2220. PubMed ID: 37709843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.
    Miller PG; Sperling AS; Mayerhofer C; McConkey ME; Ellegast JM; Da Silva C; Cohen DN; Wang C; Sharda A; Yan N; Saha S; Schluter C; Schechter I; Słabicki M; Sandoval B; Kahn J; Boettcher S; Gibson CJ; Scadden DT; Stegmaier K; Bhatt S; Lindsley RC; Ebert BL
    Blood; 2023 Dec; 142(24):2079-2091. PubMed ID: 37595362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal Hematopoiesis and risk of Acute Myeloid Leukemia.
    Desai P; Hassane D; Roboz GJ
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):177-185. PubMed ID: 31203999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of clonal hematopoiesis in remission on hematopoiesis recovery in patients with NPM1 mutated acute myeloid leukemia after chemotherapy].
    Wang LL; Chen SN
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):845-850. PubMed ID: 38049337
    [No Abstract]   [Full Text] [Related]  

  • 30. Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders.
    Awada H; Gurnari C; Visconte V; Durmaz A; Kuzmanovic T; Awada H; Tu ZJ; Cook JR; Bolwell BJ; Sobecks R; Kalaycio M; Bosler D; Maciejewski JP
    Leukemia; 2024 Jun; 38(6):1266-1274. PubMed ID: 38684821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene
    Yura Y; Miura-Yura E; Katanasaka Y; Min KD; Chavkin N; Polizio AH; Ogawa H; Horitani K; Doviak H; Evans MA; Sano M; Wang Y; Boroviak K; Philippos G; Domingues AF; Vassiliou G; Sano S; Walsh K
    Circ Res; 2021 Sep; 129(6):684-698. PubMed ID: 34315245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Zhang L; Hsu JI; Braekeleer ED; Chen CW; Patel TD; Martell AG; Guzman AG; Wohlan K; Waldvogel SM; Uryu H; Tovy A; Callen E; Murdaugh RL; Richard R; Jansen S; Vissers L; de Vries BBA; Nussenzweig A; Huang S; Coarfa C; Anastas J; Takahashi K; Vassiliou G; Goodell MA
    Elife; 2024 Jun; 12():. PubMed ID: 38896450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications.
    Hartmann L; Metzeler KH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):828-838. PubMed ID: 30939217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonal hematopoiesis: Pre-cancer PLUS.
    Silver AJ; Jaiswal S
    Adv Cancer Res; 2019; 141():85-128. PubMed ID: 30691686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.
    Gramegna D; Bertoli D; Cattaneo C; Almici C; Re A; Belotti A; Borlenghi E; Lanzi G; Archetti S; Verardi R; Brugnoni D; Sciumè M; Daffini R; Roccaro AM; Tucci A; Rossi G
    Ann Hematol; 2022 Jun; 101(6):1227-1237. PubMed ID: 35380239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of PPM1D in cancer and advances in studies of its inhibitors.
    Deng W; Li J; Dorrah K; Jimenez-Tapia D; Arriaga B; Hao Q; Cao W; Gao Z; Vadgama J; Wu Y
    Biomed Pharmacother; 2020 May; 125():109956. PubMed ID: 32006900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.